These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15648016)

  • 1. Kidney disease as an independent risk factor for cardiovascular events.
    Kumar J; Shah SV
    J Ren Nutr; 2005 Jan; 15(1):99-104. PubMed ID: 15648016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease in patients with chronic kidney disease. A clinical review.
    Kaisar M; Isbel N; Johnson DW
    Minerva Urol Nefrol; 2007 Sep; 59(3):281-97. PubMed ID: 17912225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cardiovascular risk factors in end-stage renal disease.
    Zoccali C; Mallamaci F; Tripepi G
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S77-80. PubMed ID: 14684678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients.
    Zoccali C; Enia G; Tripepi G; Panuccio V; Mallamaci F
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S84-7. PubMed ID: 16048265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia.
    Kitiyakara C; Gonin J; Massy Z; Wilcox CS
    Curr Opin Nephrol Hypertens; 2000 Sep; 9(5):477-87. PubMed ID: 10990365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular events in chronic advanced renal insufficiency. Current concepts].
    Zoccali C
    Recenti Prog Med; 2003 Mar; 94(3):125-30. PubMed ID: 12677780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease.
    Rodriguez-Iturbe B; Correa-Rotter R
    Expert Opin Pharmacother; 2010 Nov; 11(16):2687-98. PubMed ID: 20426701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic kidney disease: effects on the cardiovascular system.
    Schiffrin EL; Lipman ML; Mann JF
    Circulation; 2007 Jul; 116(1):85-97. PubMed ID: 17606856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
    Ratto E; Leoncini G; Viazzi F; Pontremoli R
    G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperhomocysteinemia as a risk factor for cardiovascular diseases in patients with chronic renal failure].
    Małecki R
    Pol Arch Med Wewn; 2000 Oct; 104(4):695-701. PubMed ID: 11392158
    [No Abstract]   [Full Text] [Related]  

  • 14. Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease.
    Apostolov EO; Basnakian AG; Ok E; Shah SV
    J Ren Nutr; 2012 Jan; 22(1):134-8. PubMed ID: 22200430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can the cardiac death rate be reduced in dialysis patients?
    Avram MM
    Semin Dial; 2002; 15(1):26-9. PubMed ID: 11874588
    [No Abstract]   [Full Text] [Related]  

  • 17. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
    Holdaas H
    Am J Cardiovasc Drugs; 2005; 5(4):255-69. PubMed ID: 15984908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy].
    Cases A; Vera M; López Gómez JM
    Nefrologia; 2002; 22 Suppl 1():68-74. PubMed ID: 11987673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients.
    Calò LA; Naso A; Carraro G; Wratten ML; Pagnin E; Bertipaglia L; Rebeschini M; Davis PA; Piccoli A; Cascone C
    Nephrol Dial Transplant; 2007 May; 22(5):1413-9. PubMed ID: 17237480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy.
    Islam KN; O'Byrne D; Devaraj S; Palmer B; Grundy SM; Jialal I
    Atherosclerosis; 2000 May; 150(1):217-24. PubMed ID: 10781654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.